Saracatinib (AZD0530)

Description: Saracatinib (formerly also known as AZD0530) is a novel, potent Src kinase inhibitor with potential antineoplastic activity. It inhibits Src with an IC50 of 2.7 nM in cell-free assays, and also potently inhibits other kinases such as c-Yes, Fyn, Lyn, Blk, Fgr and Lck; Saracatinib is less active against Abl and EGFR (L858R and L861Q). Saracatinib exhibits excellent in vivo antitumor efficacy in various tumors such as Src3T3 allografts, DU145, Calu-6, MDA-MB-231, AsPc-1 and BT474C xenografts. It has been reported to inhibit Src activation in DU145 and PC3 cell lines (prostate cancer cell lines). Both of c-Myc and cyclin D1 expression are decreased by Saracatinib. Saracatinib can inhibit the ERK1/2 and GSK3b phosphorylation as well as decrease beta-catenin level in cells. Saracatinib inhibits the prostate tumor cell growth by inducing cycle arrest at G1/S phase. Saracatinib dose-dependently blocks cell migration in DU145 and PC3 cell lines.

References: Oncogene. 2008 Oct 23; 27(49):6365-75; Mol Oncol. 2009 Jun; 3(3):248-61.

Chemical Name: N-(5-Chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine

InChi Key: OUKYUETWWIPKQR-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3, 14-16, 18H, 4-13, 17H2, 1H3, (H, 29, 30, 31)

SMILES Code: CN1CCN(CCOC2=CC3=NC=NC(NC4=C5OCOC5=CC=C4Cl)=C3C(OC6CCOCC6)=C2)CC1